Tonghua Dongbao Pharmaceutical News

Tonghua Dongbao (600867): Actively responding to changes in collection contract renewals and accelerating the promotion of innovative pipelines

招商證券Apr 28 00:00

Tonghua Dongbao (600867) 2023 Report Review: Rapid Release of New Insulin Products, Innovative Drugs, and Steady Progress in Internationalization

華創證券Apr 17 13:16

Tonghua Dongbao (600867): Rapid growth in insulin sales, steady progress in R&D and internationalization

招商證券Apr 2 07:56

Tonghua Dongbao (600867): Performance is in line with expectations, further consolidating its leading position in insulin

中金公司Apr 1 19:16

Tonghua Dongbao (600867): Innovation in stable insulin dosage and continuous breakthroughs in overseas travel

東方證券Apr 1 07:31

Tonghua Dongbao (600867): The rapid growth of third-generation insulin accelerates the internationalization of insulin

西南證券Mar 29 00:00

Tonghua Dongbao (600867): Overall increase in insulin sales, steady progress in R&D projects

國金證券Mar 28 00:00

Tonghua Dongbao (600867): Steady revenue growth in 2023

華泰證券Mar 28 00:00

Tonghua Dongbao (600867) Company Comment: Domestic Insulin Replacement Process Accelerates Performance Forecast Exceeds Expectations

國金證券Jan 29 00:00

Tonghua Dongbao (600867): Rapid increase in revenue and profit in 4Q23

華泰證券Jan 29 00:00

Tonghua Dongbao (600867): Domestic insulin replacement is expected to accelerate innovation in multiple fields+overseas commercialization to drive long-term growth

國金證券Jan 23 00:00

Research Report Nuggets | Minsheng Securities: Maintaining Tonghua Dongbao's “Recommended” Rating, Insulin Market Potential Is Huge

Gelonghui FinanceDec 8, 2023 15:57

Tonghua Dongbao (600867): Daily summary of medical industry enterprises in 2023

交銀國際Nov 28, 2023 00:00

Tonghua Dongbao (600867) 2023 Three Quarterly Report Review: Three Generations of Insulin Are Growing Rapidly, and International Business Is Progressing Steadily

中信證券Nov 3, 2023 18:42

Tonghua Dongbao (600867) 2023 Third Quarter Report Review Report: Stable Performance Growth, Steady Release of Profits

國海證券Nov 2, 2023 00:00

Tonghua Dongbao (600867): Insulin business is growing healthily, R&D and overseas travel are progressing smoothly

中金公司Nov 1, 2023 18:42

Tonghua Dongbao (600867) 2023 Three Quarter Report Review: Insulin Sales Continues to Grow, R&D Pipeline Achievements Gradually Realize

民生證券Oct 31, 2023 00:00

Tonghua Dongbao (600867): Steady growth in performance accelerates the internationalization process

西南證券Oct 30, 2023 00:00

Tonghua Dongbao (600867): Revenue and profit are growing under pressure in 3Q23

華泰證券Oct 30, 2023 00:00

Tonghua Dongbao (600867) Review of important matters: Cooperating with bodybuilders to enter the US insulin market and accelerate the internationalization process

華創證券Sep 24, 2023 00:00